Active — Not RecruitingPhase 3

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

United States149 participantsStarted 2025-04-14

Plain-language summary

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge

Who can participate

Age range

18 Years – 74 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Diagnosis of MDD per DSM-5
. Male or female aged 18 to 74
. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration
. MADRS Total Score ≥26
. CGI-S Score ≥4

Exclusion criteria

. Certain psychiatric disorders (other than major depressive disorder)
. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine
. Any clinically significant unstable illness

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6

Timeframe: Baseline to Week 6

Trial details

NCT IDNCT06941844

SponsorDefinium Therapeutics US, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05-20

View on ClinicalTrials.gov More Major Depressive Disorder trials